The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy

被引:14
作者
Zhou, Wenbin [1 ]
Ding, Qiang [1 ]
Liang, Xiuqing [1 ]
He, Zhongyuan [1 ]
Zha, Xiaoming [1 ]
Liu, Xiaoan [1 ]
Wang, Shui [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Surg, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; YOUNG-WOMEN; DOCETAXEL; SURVIVAL; ANTHRACYCLINE; FERTILITY; THERAPY; DOXORUBICIN; TRIAL;
D O I
10.1371/journal.pone.0037249
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed. Methodology and Principal Findings: Between October 2008 and March 2010, 186 consecutive premenopausal patients, treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34-40.88, P < 0.001) and previous childbearing (OR: 3.17, 95% CI: 1.06-9.47, P = 0.038) were significantly associated with probability of CIA. Compared to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate of CIA (P > 0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group (34.62%) (P = 0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P = 0.037). Conclusions: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-induced infertility.
引用
收藏
页数:5
相关论文
共 34 条
[1]   Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens [J].
Alejandro Perez-Fidalgo, Jose ;
Rosello, Susana ;
Garcia-Garre, Elisa ;
Jorda, Esther ;
Martin-Martorell, Paloma ;
Bermejo, Begona ;
Chirivella, Isabel ;
Guzman, Cecilia ;
Lluch, Ana .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (01) :245-251
[2]   Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer [J].
Amadori, Dino ;
Silvestrini, Rosella ;
De Lena, Mario ;
Boccardo, Francesco ;
Rocca, Andrea ;
Scarpi, Emanuela ;
Schittulli, Francesco ;
Brandi, Mario ;
Maltoni, Roberta ;
Serra, Patrizia ;
Ponzone, Riccardo ;
Biglia, Nicoletta ;
Gianni, Lorenzo ;
Tienghi, Amelia ;
Valerio, Maria Rosaria ;
Bonginelli, Paola ;
Amaducci, Laura ;
Faedi, Marina ;
Baldini, Editta ;
Paradiso, Angelo .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) :775-784
[3]   Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel [J].
Berliere, Martine ;
Dalenc, Florence ;
Malingret, Nathalie ;
Vindevogel, Anita ;
Piette, Philippe ;
Roche, Henry ;
Donnez, Jacques ;
Symann, Michel ;
Kerger, Joseph ;
Machiels, Jean-Pascal .
BMC CANCER, 2008, 8 (1)
[4]   How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to Cryopreservation of embrya, oocytes, or ovaries [J].
Blumenfeld, Zeev .
ONCOLOGIST, 2007, 12 (09) :1044-1054
[5]   Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer [J].
Cameron, DA ;
Massie, C ;
Kerr, G ;
Leonard, RCF .
BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1837-1842
[6]   Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer [J].
Di Cosimo, S ;
Alimonti, A ;
Ferretti, G ;
Sperduti, I ;
Carlini, P ;
Papaldo, P ;
Fabi, A ;
Gelibter, A ;
Ciccarese, M ;
Giannarelli, D ;
Mandalá, M ;
Milella, M ;
Ruggeri, EM ;
Cognetti, F .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1065-1071
[7]  
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2005, LANCET, V365, P1687, DOI [10.1016/S0140-6736(05)66544-0, DOI 10.1016/S0140-6736(05)66544-0]
[8]   Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane [J].
Fornier, MN ;
Modi, S ;
Panageas, KS ;
Norton, L ;
Hudis, C .
CANCER, 2005, 104 (08) :1575-1579
[9]   Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer [J].
Han, Hye-Suk ;
Ro, Jungsil ;
Lee, Keun Seok ;
Nam, Byung-Ho ;
Seo, Jung Ae ;
Lee, Dae Hee ;
Lee, Honggi ;
Lee, Eun Sook ;
Kang, Han Sung ;
Kim, Seok Won .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :335-342
[10]   Maintaining Fertility in Young Women with Breast Cancer [J].
Hulvat, Melissa C. ;
Jeruss, Jacqueline S. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2009, 10 (5-6) :308-317